Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients
✍ Scribed by Katalin Csoka; Peter Nygren; Wilhelm Graf; Lars Påhlman; Bengt Glimelius; Rolf Larsson
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- French
- Weight
- 571 KB
- Volume
- 63
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
The antineoplastic activity of suramin is currently the subject of clinical trials. We therefore used the semi-automated fluorometric microculture cytotoxicity assay (FMCA) to evaluate the cytotoxicity of suramin in vitro in primary cultures of cells from patients with hematological or solid tumors. The activity patterns of some standard cytotoxic agents were included for comparison. A total of I59 samples were tested using continuous drug exposure. Surarnin showed relatively high activity against solid tumors, with colorectal, adrenal and kidney carcinomas being the most sensitive, whereas hematological malignancies were more resistant. Surarnin and standard drugs showed very low cross-resistance. The results indicate that suramin is differentially active against some solid tumors with comparatively little activity against hematological tumors. The study provides an experimental motive for evaluation of suramin therapy in patients with solid tumors and exploration of less toxic suramin analogues.
📜 SIMILAR VOLUMES
The semi-automated fluorometric microculture cytotoxicity assay (FMCA), based on the measurement of fluorescence generated from cellular hydrolysis of fluorescein diacetate (FDA) by viable cells, was employed for cytotoxic drug sensitivity testing of tumor cells from patients with hematological or s
Progression from a steroid sensitive to insensitive state is characteristic of breast tumors, but little is known about the molecular mechanisms involved. Changes in steroid receptor can be associated with the progression. This paper reviews the cell culture data pertaining to loss of response and c
We established gastric cancer-specific CD8 1 T-cell (T CD8 1) lines derived from different lymphocyte sources in the same patients by repeated stimulation with mitomycin-C-treated autologous tumor cells with low-dose interleukin-2, and we compared recognition patterns among the T CD8 1 derived from
BACKGROUND. Low frequency epithelial cells in bone marrow from
The authors established five cell lines from a human head and neck tumor. The five cell lines (HC-2, HC-3, HC-4, HC-7, and HC-9) exhibited different sensitivities to Adriamycin, cisplatin, bleomycin, 5- fluorouracil, vincristine, and daunomycin. The Dw was 200 ng/ml Adriamycin (doxorubicin) for HC-7